Delcambre Sylvie, Ghelfi Jenny, Ouzren Nassima, Grandmougin Léa, Delbrouck Catherine, Seibler Philip, Wasner Kobi, Aasly Jan O, Klein Christine, Trinh Joanne, Pereira Sandro L, Grünewald Anne
Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg.
Front Neurol. 2020 Aug 25;11:881. doi: 10.3389/fneur.2020.00881. eCollection 2020.
Several mutations in leucine-rich repeat kinase-2 (LRRK2) have been associated with Parkinson's disease (PD). The most common substitution, G2019S, interferes with LRRK2 kinase activity, which is regulated by autophosphorylation. Yet, the penetrance of this gain-of-function mutation is incomplete, and thus far, few factors have been correlated with disease status in carriers. This includes (i) LRRK2 autophosphorylation in urinary exosomes, (ii) serum levels of the antioxidant urate, and (iii) abundance of mitochondrial DNA (mtDNA) transcription-associated 7S DNA. In light of a mechanistic link between LRRK2 kinase activity and mtDNA lesion formation, we previously investigated mtDNA integrity in fibroblasts from manifesting (LRRK2+/PD+) and non-manifesting carriers (LRRK2+/PD-) of the G2019S mutation as well as from aged-matched controls. In our published study, mtDNA major arc deletions correlated with PD status, with manifesting carriers presenting the highest levels. In keeping with these findings, we now further explored mitochondrial features in fibroblasts derived from LRRK2+/PD+ ( = 10), LRRK2+/PD- ( = 21), and control ( = 10) individuals. In agreement with an accumulation of mtDNA major arc deletions, we also detected reduced NADH dehydrogenase activity in the LRRK2+/PD+ group. Moreover, in affected G2019S carriers, we observed elevated mitochondrial mass and mtDNA copy numbers as well as increased expression of the transcription factor (), which regulates antioxidant signaling. Taken together, these results implicate mtDNA dyshomeostasis-possibly as a consequence of impaired mitophagy-in the penetrance of LRRK2-associated PD. Our findings are a step forward in the pursuit of unveiling markers that will allow monitoring of disease progression of LRRK2 mutation carriers.
富含亮氨酸重复激酶2(LRRK2)中的几种突变与帕金森病(PD)相关。最常见的替代突变G2019S会干扰LRRK2激酶活性,而该活性受自身磷酸化调节。然而,这种功能获得性突变的外显率并不完全,迄今为止,很少有因素与携带者的疾病状态相关。这包括:(i)尿外泌体中的LRRK2自身磷酸化;(ii)抗氧化剂尿酸的血清水平;(iii)线粒体DNA(mtDNA)转录相关的7S DNA的丰度。鉴于LRRK2激酶活性与mtDNA损伤形成之间的机制联系,我们之前研究了G2019S突变的显性携带者(LRRK2+/PD+)和非显性携带者(LRRK2+/PD-)以及年龄匹配的对照者成纤维细胞中的mtDNA完整性。在我们已发表的研究中,mtDNA主环缺失与PD状态相关,显性携带者的缺失水平最高。与这些发现一致,我们现在进一步探究了来自LRRK2+/PD+(n = 10)、LRRK2+/PD-(n = 21)和对照(n = 10)个体的成纤维细胞中的线粒体特征。与mtDNA主环缺失的积累一致,我们在LRRK2+/PD+组中还检测到NADH脱氢酶活性降低。此外,在受影响的G2019S携带者中,我们观察到线粒体质量和mtDNA拷贝数增加,以及调节抗氧化信号的转录因子TFAM的表达增加。综上所述,这些结果表明mtDNA动态平衡失调——可能是线粒体自噬受损的结果——与LRRK2相关PD的外显率有关。我们的发现朝着揭示能够监测LRRK2突变携带者疾病进展的标志物迈出了一步。